Multi-source·Jul 21, 2026·3 sources analyzed
FTC reached a proposed settlement with Caremark over insulin pricing
The Federal Trade Commission says CVS Caremark must change rebate and fee practices tied to insulin prices, and the proposed consent order is part of the agency's continuing case against major pharmacy benefit managers. (sources: www.ftc.gov)
Image: Modern Action subject: Prescription drug prices
Modern Action Briefing
The FTC's proposed consent order addresses antitrust concerns related to Caremark's role as a pharmacy benefit manager in insulin pricing.
- The FTC has secured a proposed settlement with Caremark.
- The settlement is part of an antitrust case against Caremark.
- A 30-day public comment window has been established for the proposed consent order.
Why it matters
The settlement aims to address pricing practices in the insulin market, potentially impacting access and affordability for consumers.
Connected public decisions
Follow the issue pages where this story connects to public action.
Contact officials
Act on Prescription drug prices
See the current decision, choose your position, and send a message through the issue page.
Take action on Prescription drug prices